Auto-injectors Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 10.84 Billion |
| Market Size (2029) | USD 22.83 Billion |
| CAGR (2024 - 2029) | 16.05 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Auto-injectors Market Analysis
The Global Auto-Injectors Market size is estimated at USD 10.84 billion in 2024, and is expected to reach USD 22.83 billion by 2029, growing at a CAGR of 16.05% during the forecast period (2024-2029).
The COVID-19 pandemic has exerted favorable and unfavorable impacts on the healthcare industry. This is likely because most autoinjector products are administered at home by the patient. Patients who use autoinjectors don't have to leave their homes to receive care, which is advantageous when trying to maintain social distance during the pandemic. The rising COVID-19 patient population is putting a strain on hospital systems and the availability of medical supplies for each patient and the hospital. Due to increased demand for medical supplies such as injections, pre-filled syringes, and other items, manufacturers have increased their production capacity to meet the demand-supply balance. Covid-19 has had a significant impact on the market for auto-injectors.
The factors that are driving the market growth include increasing demand for the convenience of patients, rising incidence of chronic and lifestyle diseases, and technological advancements. According to World Health Organization Reports, in 2021, over 16 billion injections were given annually worldwide. Thus, the rising number of injections annually drives the demand for auto-injectors, thereby boosting the market.
According to the World Health Organization (WHO), the prevalence of chronic diseases is expected to rise by 57% by 2020, and 60% of this burden is likely to occur in emerging markets. Chronic diseases (CD) of various types are found to be the leading causes of disability and morbidity around the world. According to the Globocan 2020 report, 19,292,789 new cancer cases were diagnosed worldwide, with 9,958,133 cancer-related deaths. Furthermore, according to the International Diabetes Federation Report in December 2021, Diabetes affects approximately 537 million adults aged 20 to 79. By 2030, the total number of diabetics is expected to reach 643 million; by 2045, it will reach 783 million. Three out of every four adults with diabetes live in a low- or middle-income country. Moreover, according to the World Health Organization 2020 report, in 2020, it was estimated that around 10 million people suffered from tuberculosis globally. This includes 5.6 million men, 3.3 million women, and 1.1 million children. Tuberculosis affects people of all ages and from all countries. The 30 most affected countries by tuberculosis accounted for 86% of new cases in 2020. India leads the pack with two-thirds of the total, followed by China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa. Thus, the increase in the number of chronic diseases boosts the market growth over the forecast period.
The use of an auto-injector has brought many benefits for both the patient and healthcare professional. It has simplified self-administration, reduced anxiety, improved safety, and improved compliance. Furthermore, with the tremendous opportunity in the market, many market players are adopting various strategies, such as collaborations, acquisitions, new product launches, and expansions. For instance, in September 2021, Owen Mumford Pharmaceutical Services, a division of Owen Mumford Ltd, launched its new Aidaptus auto-injector platform following the successful completion of development. Additionally, in July 2021, Otsuka Pharmaceutical Co., Ltd. (Otsuka) applied to Japan's Ministry of Health, Labour, and Welfare for an additional dosage form, auto-injector, for AJOVY Subcutaneous Injection 225 mg (a generic name is fremanezumab).
Thus, the abovementioned factors are expected to drive market growth over the forecast period. However, preference for alternative dosage delivery modes and regulatory hurdles may hinder the growth of the market.
Auto-injectors Market Trends
This section covers the major market trends shaping the Auto-Injectors Market according to our research experts:
Rheumatoid Arthritis Expected to Hold Significant Market Share Over the Forecast Period
Rheumatoid arthritis (RA) is an autoimmune disease in which the body's immune system attacks the joints, causing inflammation of the synovium and swelling and pain in and around the joints. Arthritis primarily affects the elderly population, with females having a higher prevalence than males. According to the United Nations World Population Prospects 2020 report, 727 million people are living in the world aged 65 years or above, and this number is expected to become more than double by the year 2050. As arthritis is more prevalent in the geriatric population and increasing it boosts the segment over the forecast period.
According to several recent studies, the majority of the patients with rheumatoid arthritis who used an autoinjector for the treatment were observed to be comfortable using the device and even had better outcomes than those who had someone else administer injections. Additionally, the initiatives by the market players are also propelling the growth of the market. For Instance, in March 2022, NORDIC PHARMA, a SEVER Life Sciences company, submitted a New Drug Submission to Health Canada for its methotrexate auto-injector, Nordimet for the treatment of severe disabling active rheumatoid arthritis (RA) and symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy). Approval of such drugs is expected to propel the growth of the market.
Thus, owing to the abovementioned factors, the market segment is expected to show growth over the forecast period.
North America Expected to Dominate the Market Over the Forecast Period
North America is expected to hold a significant share of the global disposable auto-injectors market during the forecast period. The factors such as early adoption of technologically advanced products and product approvals as well rising prevalence of chronic diseases boost the market in the region. A high incidence of chronic diseases, such as cancers, boosts the market in the region. According to the Globocon 2020, the number of new cancer cases diagnosed was 2,281,658 in the United States in 2020, with 612,390 deaths. Among all cancers, breast cancer had the highest incidence with 253,465 cases, followed by lung (227,875), prostate (209,512), and colon (101,809).
Furthermore, rising technological advancements, increasing entry of new players, and speedy adoption of advanced products are helping in the market growth in the United States. For example, in April 2020, Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. reported the availability of the autoinjector device for AJOVY (fremanezumab-vfrm) injection in the United States. AJOVY is indicated for the preventive treatment of migraine in adults and is the only anti-CGRP (calcitonin gene-related peptide) preventive migraine treatment with quarterly (675 mg) and monthly (225 mg) subcutaneous dosing options.
Thus, owing to the abovementioned factors, the North American region is expected to project growth over the forecast period.
Auto-injectors Industry Overview
The Auto-Injectors market is highly competitive and consists of several major players. Companies like Abbvie, Amgen, AstraZeneca, Bayer, Becton, Dickinson and Company, Biogen, Eli Lilly, Novartis, Teva Pharmaceuticals, and Ypsomed, among others, hold a substantial market share in the Auto-Injectors market.
Auto-injectors Market Leaders
-
Ypsomed
-
Abbvie
-
Amgen
-
Teva Pharmaceuticals
-
Biogen
*Disclaimer: Major Players sorted in no particular order
Auto-injectors Market News
- In May 2022, Jabil Healthcare, a division of Jabil Inc. launched the Qfinity autoinjector platform, a simple, reusable, and modular solution for subcutaneous (SC) drug self-administration, at a lower cost than market alternatives.
- In May 2022, Stevanato Group S.p.A. signed an exclusive agreement with one of the leading medical device developers and manufacturers Owen Mumford Ltd. for its Aidaptus auto-injector.
Auto-injectors Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definitions
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Demand for Convenience of Patients
- 4.2.2 Rising Incidence of Chronic and Lifestyle Diseases
- 4.2.3 Technological Advancements
-
4.3 Market Restraints
- 4.3.1 Preference for Alternative Drug Delivery Modes
- 4.3.2 Regulatory Hurdles
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Application
- 5.1.1 Rheumatoid Arthritis
- 5.1.2 Multiple Sclerosis
- 5.1.3 Anaphylaxis
- 5.1.4 Other Applications (Cardiovascular Diseases, Diabetes, Migraines, Psoriasis, and Anemia)
-
5.2 By Type
- 5.2.1 Disposable Autoinjectors
- 5.2.2 Reusable Autoinjectors
-
5.3 By End User
- 5.3.1 Home Care Settings
- 5.3.2 Hospital & Clinics
- 5.3.3 Other End Users
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbvie
- 6.1.2 Amgen
- 6.1.3 AstraZeneca
- 6.1.4 Bayer
- 6.1.5 Becton, Dickinson and Company
- 6.1.6 Biogen
- 6.1.7 Eli Lilly
- 6.1.8 Novartis
- 6.1.9 Teva Pharmaceuticals
- 6.1.10 Ypsomed
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAuto-injectors Industry Segmentation
Auto-Injector refers to a syringe that contains a spring-loaded needle, generally with a preloaded dose of medication. Upon being forced against the body with a piercing motion, the device gets activated and administers a calculated dose of medication. Autoinjectors are usually used for self-administration of epinephrine (to mitigate anaphylaxis); by migraine sufferers who want quick relief of headache, or even by the military and emergency services workers to combat the effects of nerve agents. The auto-injectors market is segmented by Application (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, and Others), Type (Disposable Autoinjectors and Reusable Autoinjectors), End User (Home Care Settings, Hospital and Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.
| By Application | Rheumatoid Arthritis | |
| Multiple Sclerosis | ||
| Anaphylaxis | ||
| Other Applications (Cardiovascular Diseases, Diabetes, Migraines, Psoriasis, and Anemia) | ||
| By Type | Disposable Autoinjectors | |
| Reusable Autoinjectors | ||
| By End User | Home Care Settings | |
| Hospital & Clinics | ||
| Other End Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Auto-injectors Market Research FAQs
How big is the Global Auto-Injectors Market?
The Global Auto-Injectors Market size is expected to reach USD 10.84 billion in 2024 and grow at a CAGR of 16.05% to reach USD 22.83 billion by 2029.
What is the current Global Auto-Injectors Market size?
In 2024, the Global Auto-Injectors Market size is expected to reach USD 10.84 billion.
Who are the key players in Global Auto-Injectors Market?
Ypsomed, Abbvie, Amgen, Teva Pharmaceuticals and Biogen are the major companies operating in the Global Auto-Injectors Market.
Which is the fastest growing region in Global Auto-Injectors Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Auto-Injectors Market?
In 2024, the North America accounts for the largest market share in Global Auto-Injectors Market.
What years does this Global Auto-Injectors Market cover, and what was the market size in 2023?
In 2023, the Global Auto-Injectors Market size was estimated at USD 9.34 billion. The report covers the Global Auto-Injectors Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Auto-Injectors Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Autoinjectors Industry Report
Statistics for the 2024 Autoinjectors market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Autoinjectors analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
